Gene knock outs (KOs) are efficiently engineered through CRISPR-Cas9-induced frameshift mutations. While the efficiency of DNA editing is readily verified by DNA sequencing, a systematic understanding of the efficiency of protein elimination has been lacking. Here we devised an experimental strategy combining RNA sequencing and triple-stage mass spectrometry to characterize 193 genetically verified deletions targeting 136 distinct genes generated by CRISPR-induced frameshifts in HAP1 cells. We observed residual protein expression for about one third of the quantified targets, at variable levels from low to original, and identified two causal mechanisms, translation reinitiation leading to N-terminally truncated target proteins or skipping of the edited exon leading to protein isoforms with internal sequence deletions. Detailed analysis of three truncated targets, BRD4, DNMT1 and NGLY1, revealed partial preservation of protein function. Our results imply that systematic characterization of residual protein expression or function in CRISPR-Cas9-generated KO lines is necessary for phenotype interpretation.
F ollowing the development of CRISPR-based technology [1] [2] [3] , genome editing has become a widely accessible tool for biological research. The technology is based on an RNA-guided enzyme, such as the nuclease Cas9, bound by a short guide RNA (sgRNA) that provides sequence specificity 4 .
One of the most common CRISPR-Cas9 applications is the generation of a genetic KO by the introduction of a frameshift mutation. The Cas9-sgRNA complex is targeted to a specific sequence in the coding region of a gene and cleaves both strands of the DNA 5, 6 . The DNA double-stranded break is repaired by non-homologous end joining, an error-prone pathway introducing insertion or deletion mutations that can lead to frameshifts 7 and a premature termination codon (PTC) in the expressed transcript, resulting in nonsense-mediated decay (NMD) of the mRNA and aberrant peptide products that are degraded 8 .
Multiple studies have investigated potential off-target effects of CRISPR-Cas9 [9] [10] [11] [12] [13] . Collectively, these studies report sgRNAdependent off-target effects at rates that can be comparable to ontarget editing. These findings triggered developments to improve CRISPR-Cas9 specificity by the use of Cas9 nickase-variants 12, 14, 15 , improvements in sgRNA design 12, 13, 16, 17 and protein engineering of the nuclease 18, 19 .
The editing efficiency of CRISPR-Cas9 is commonly assessed on the genomic level. However, many current study designs do not further assess whether the induced frameshift mutation results in the complete loss of protein expression and activity that is expected. Here we systematically characterized the effects of frameshift KO mutations. We studied 193 isogenic KOs in HAP1 cells by quantitative transcriptomics and proteomics. Although all KOs contained frameshifts, about one third of them still expressed the target protein, albeit the majority at reduced levels. Similarly, we detected residual target expression for a CRISPR-Cas9 KO in a K562 cell line. A detailed analysis of three of the KO lines (BRD4, DNMT1 and NGLY1) revealed that the detected protein products were truncated but preserved partial functionality.
Results
Systematic characterization of frameshift KO mutations. We investigated 193 HAP1 lines, in each of which one of 136 genes was targeted by CRISPR-Cas9 to induce a frameshift KO mutation. All lines were derived from the near-haploid human cell line HAP1, which contains a single copy of most genomic loci and is an attractive model system to trace genome-editing events [20] [21] [22] . In a first experiment, RNA expression levels of 174 of the mutants and the parental line were measured using 3′ RNA sequencing 23 (3′-RNAseq; Fig. 1a ). In each KO line, we considered the transcripts originating from the targeted gene and calculated the ratio between the expression level in the KO and the parental lines, which we termed the residual level. A residual level of 0 indicates complete elimination, a value of 1 indicates a target transcript level as high as in the parental line. Contrary to our expectation, the 174 residual levels did not concentrate near 0, but covered a wide range. Thus, in many KO lines the mutant mRNA was not strongly reduced. As in all lines the presence of a PTC was confirmed by DNA sequencing, this implies that there was no or weak NMD response to these transcripts. This finding is in line with a recent study that reported high variation in NMD efficiency depending on a complex set of biological factors 24 .
Next, we performed an analogous analysis for the target protein levels by tandem mass tag (TMT) isobaric labeling combined with triple-stage mass spectrometry 25 (MS3) ( Fig. 1a ). We first benchmarked our method with a control experiment in which we spiked Escherichia coli into a human protein background in different ratios and verified that low protein levels were accurately quantified by the MS3 method ( Supplementary Fig. 1a -c). To assess specificity, we considered the distribution of E. coli protein quantifications in a human-only sample. While ideally these should all be zero, for 8% (49 of 587), the quantification exceeded 0.1 of the value in the E. coli-only sample (Supplementary Fig. 1f and Supplementary  Table 1 ). On this basis, we chose a quantification ratio between KO and parental line of 0.1 as a threshold for calling residual expression and assumed that this would similarly imply a false-positive rate of around 8% ( Supplementary Fig. 1d,e) .
Surprisingly, about one third of the KO lines displayed residual protein levels above this threshold (Fig. 1a) , and there was no correlation between residual RNA and protein levels, indicating that the residual RNA level is not predictive of the residual protein level. We selected an additional set of 19 lines for quantification with wholetranscript RNA-seq and MS3 ( Fig. 1b ). Each of these quantifications was done with at least two replicates, and replicates were highly consistent ( Supplementary Figs. 2 and 3 ). Similarly to the observation in Fig. 1 , there was little correlation between residual RNA and protein levels. Moreover, the residual levels were not dependent on their initial levels before CRISPR modification, as measured by the number of RNA-seq reads and the MS1 intensities (determined by the TOP3 method 26 ) of the parental samples ( Fig. 1c ).
Residual protein expression owing to exon skipping. The MTF2 104bp , PI4KB and BRD3 KO lines showed residual protein levels ranging from 9 to 28% (Fig. 1b) . The transcript level of PI4KB was reduced, whereas MTF2 104bp and BRD3 displayed levels close to the wild type. Therefore, we assessed whether the mutant lines expressed alternative transcripts that skip the edited exon ( Fig. 2a-c) .
The BRD3 transcript in the BRD3 KO line contained exon-exon junction reads spanning from the 5′ untranslated region (UTR) to the second coding exon (11 of 66 reads mapping to this junction) and from the 5′ UTR to the third coding exon (6 of 66 reads) ( Fig. 2a ). This splicing event removes from the transcript both the start codon and the frameshift mutation. Our data suggest that the 5′ UTR is extended and Met81 or Met125 are used as alternative start codons giving rise to a N-terminally truncated BRD3 protein.
In the MTF2 104bp line, the 104-base-pair (bp) insertion and associated frameshift induced a strong alternative splicing event ( Fig. 2b ). Exon 5, which contains the frameshift mutation, was skipped (60 of 76 reads). Strikingly, this did not occur in another line generated using the same sgRNA, where MTF2 was mutated with a 1-bp insertion (Fig. 2b ). Deletion of exon 5, which is 101 nucleotides long, will lead to a frameshift downstream of the exon. Interestingly, there is an out-of-frame ATG in exon 4 (chromosome 1: 93,114,751-93,114,753, Genome Reference Consortium Human Build 38), which after skipping of exon 5 would result in an inframe transcript from exon 6 onward. This ATG could explain the observed residual protein expression in the MTF2 104 bp line, by giving rise to a protein isoform that omits the original first 160 amino acids and instead starts with ten alternative amino acids originating from exon 4.
The PI4KB frameshift mutation resulted in low-level expression of a splice variant skipping the frameshift-containing exon 5 ( Fig. 2c ), causing an in-frame deletion of 228 bp (76 amino acids). This splicing event only occurred in ~7% of PI4KB transcripts (3 of 42 exon-exon junction reads). This result suggests that the low-level residual protein originates from the alternatively spliced transcript. 
Residual level BRD4 frameshift mutation leads to a partially functional truncated protein by translation reinitiation. The BRD4 KO line contained a 16-bp deletion in exon 2 ( Supplementary Table 2 ) and showed residual RNA and protein expression ( Fig. 1b ). However, we did not find evidence for exon skipping (Fig. 2d ). To further characterize the residual protein, we looked at residual expression of different regions of BRD4, on the basis of the quantified tryptic peptides. The mutant expressed low levels of the N-terminal region, corresponding to the exons before and around the CRISPR-Cas9 target site ( Fig. 2e ). The region in the C-terminal direction of the target site displayed residual expression levels higher than 10%. These data suggest N-terminal truncation of BRD4 as a consequence of translation reinitiation 24, 27, 28 . We confirmed the residual expression of BRD4 by immunoblot, revealing a smaller protein product with an intensity of approximately 15% ( Supplementary Fig. 4a ). BRD4 immunoprecipitations with two different BRD4 antibodies enriched both the wild-type and the truncated product, in line with the BRD4 identity of the truncated protein ( Supplementary Fig. 4a ). The abundance levels of the quantified peptides and the size of the truncated protein support the explanation that translation of the protein is reinitiated at Met105, Met107 or Met132 ( Supplementary  Fig. 4b ). Notably, Met105 is highly conserved across the bromodomain protein family 29 . For BRD2, a putative isoform is described starting at the methionine corresponding to Met105 in BRD4 30 . Additionally, one of the identified BRD3 truncations ( Fig. 2a ) starts at Met81, which also corresponds to Met105 in BRD4. Altogether, these properties of Met105 suggest it as a plausible candidate for initiating an N-terminally truncated protein product. The truncated isoform lacks the initial 30 amino acids (41%) of the first bromodomain (BD1), which is crucial for binding of BRD4 to acetylated histone H4 (ref. 29 ). To test whether the truncated protein retained any functionality, we performed binding assays with a histone H4 N-terminal peptide and with a small molecule bromodomain inhibitor (I-BET). I-BET binds to the bromodomains of BRD4 and other BET proteins with similar affinity 31, 32 . Sepharose beads derivatized with I-BET bound to wild-type and truncated BRD4 as expected, as the truncated protein still comprised the second bromodomain (BD2) (Fig. 2f ). By contrast, the triple-acetylated histone H4 tail peptide, which binds to BD1, bound to wild-type but not truncated BRD4 (Fig. 2f ). These results confirm the loss of BD1 and the preservation of a functional BD2 in the BRD4 KO.
DNMT1 frameshift mutation leads to retained DNMT1 activity.
Two DNA methyltransferase 1 (DNMT1) KO lines were assayed by RNA-seq and proteomics (Fig. 1b) . The DNMT1 5bp line has a 5-bp deletion in exon 6 (Supplementary Table 2 ) and showed residual peptide levels of about 40% nearly uniformly throughout the gene body ( Fig. 3a ). Although we observed three reads supporting skipping of the 79-bp-long CRISPR-targeted exon ( Supplementary  Fig. 5a ), this would still lead to a frameshift in the spliced transcript. Instead, the peptide-level expression pattern is better explained by two truncated proteins. The deletion results in a stop codon directly downstream of the CRISPR target site, leading to a C-terminally truncated protein product consisting of the first 188 amino acids. This is validated by the complete absence of the RKPQEESER peptide (amino acids 178-186) in the data for the KO, but not the wild-type line. Although the peptide is still present in the truncated protein product, its new location close to the C-terminal end (RKPQEESERAKstop) results in a modified cleavage context for trypsin. Thus, the peptide is no longer preferentially generated and quantified. A second, N-terminally truncated protein is explained by intron retention. The first quantified peptide downstream of the CRISPR target site is located at the end of exon 8 (peptide EEERDEK, amino acids 234-240). Retention of the intron between exons 7 and 8 creates three in-frame methionines that could be used for translation reinitiation; this hypothesis is in line with annotation of DNMT1 with twelve transcripts that contain retained introns 33 .
The DNMT1 20bp line has a 20-bp deletion in exon 4 and here we did not find evidence for excision of the targeted exon ( Supplementary  Fig. 5b ). The nearly uniform residual peptide level of about 10% throughout the gene body (Fig. 3b) is close to the noise threshold established in the MS3 benchmark ( Supplementary Fig. 1 ).
To assess the residual protein activity of both mutant lines, we measured genome-wide methylation levels using methylation arrays. DNMT1, the main protein involved in maintenance of DNA methylation, copies pre-existing methylation marks onto hemimethylated DNA strands during DNA synthesis 34 . The DNMT1 5bp line showed methylation levels similar to the wild type ( Fig. 3c) , consistent with residual protein activity. By contrast, the DNMT1 20bp line showed little to no evidence of DNA methylation (Fig. 3c ).
Treating the DNMT1 20bp line with the DNMT1 inhibitor RG-108 did not change its methylation levels, consistent with already complete abrogation of DNMT1 methylation activity. These results show that the DNMT1 5bp KO line has residual protein activity.
NGLY1 frameshift mutation results in a partially functional NGLY1 truncation. To extend the analysis to a second cell type, we assessed frameshift KO mutations of the NGLY1 gene, which encodes a de-N-glycosylating enzyme, in K562 cells (Fig. 4) . Two KO clones termed NGLY1 c15 and NGLY1 c20 , which each resulted from expansion of a single cell, were isolated. Quantitative mass spectrometry, did not detect residual target protein expression ( Fig. 4a ). RNA-seq revealed skipping of exon 3, which in both clones contained the frameshift mutation (Fig. 4b ). Skipping of this exon results in an in-frame deletion of 246 bp, leading to a truncated protein missing Gly74 to Thr155. Although we did not detect residual protein expression, the expression of the in-frame exon-3-skipping transcript led us to investigate potential residual function of the target enzyme by a deglycosylation assay 35 . Both NGLY1 KO lines showed deglycosylation activity, albeit reduced to 60-65% as compared to wild-type cells (Fig. 4c ). Addition of the NGLY1 inhibitor zVAD-FMK 36 further reduced deglycosylation (Fig. 4c ). To rule out nonspecific effects of zVAD-FMK, we generated patient-derived 37 , termed m01, and frameshift, termed m03 and m14, mutations in NGLY1 exon 8, that completely abrogated deglycosylation activity (Fig. 4c) . Indeed, zVAD-FMK treatment did not further reduce deglycosylation in these clones (Fig. 4c) . These results indicate that the cells of the clones NGLY1 c15 and NGLY1 c20 had reduced, but measurable, NGLY1-based deglycosylation activity.
Discussion
We summarize our findings in a model that delineates the possible effects of frameshift KO mutations (Fig. 5 ). Our first striking observation was the heterogeneity in NMD efficiency in the KO lines. 
Fig. 4 | NGLY1 frameshift mutation in K562 cells results in a partially functional NGLY1 truncation. a,
Residual RNA and protein levels of the two NGLY1 frameshift mutation K562 lines. Residual RNA levels were determined from a single RNA-seq experiment, residual protein levels were derived from all spectra assigned to the protein in a single mass spectrometry measurement. b, Exon usage and splicing of the NGLY1 transcript in these and the parental lines. c, Deglycosylation-dependent Venus fluorescence assay results for the wild-type and NGLY1 frameshift mutant lines stably expressing the ddVenus reporter. zVAD-FMK, NGLY1 inhibitor; c15 and c20, clones with frameshift mutations in exons 1 and 3; m01, clone with a patient-derived 37 mutation; m03 and m14, clones with a mutation in exon 8.
Both alternative splicing, which deletes the PTC from the transcript, and translation reinitiation appeared as causes for incomplete NMD efficiency. However, even in the lines without residual protein expression, NMD efficiency-as assessed by residual RNA level-was variable. This observation is in line with a recent study reporting multiple mechanisms influencing NMD efficiency 24 , and indicates that frameshift mutations can lead to full disruption of the protein despite no or weak NMD.
The second striking observation was the residual protein expression in about one third of the KO lines. We identified skipping of the frameshift mutation in the transcript by alternative splicing in four characterized lines. This is in line with previous reports 38, 39 and identifies this mechanism as a major source of KO evasion. Moreover, we identified residual protein expression as a consequence of translation reinitiation in three of the KO lines ( Fig. 5 ), in line with a report by Makino et al 28 . The production of truncated proteins by alternative splicing and/or translation reinitiation is an important potential limitation of the CRISPR technology used here. However, it should be possible to at least partially suppress or circumvent these mechanisms by adapting the experimental design, for instance, by using combinations of sgRNAs and/or modifying splicing sites.
We observed that transcript levels of the frame-shifted gene are not predictive of protein levels. The mass-spectrometry-based method applied here has a high signal-to-noise ratio 25 and is able to resolve multiple peptides in different regions of a protein. It is more sensitive and less biased than immunoblotting, which is limited to the epitope of the antibody. As illustrated by the BRD4 KO immunoblot ( Supplementary Fig. 4a ), proteins that have lower expression levels and truncated proteins are easily overlooked. Therefore, we recommend characterization of KO lines generated using CRISPR-Cas9-induced frameshifts by high-resolution mass spectrometry.
Residual protein expression of the alternatively spliced NGLY1 frameshift mutation clones was not detected by mass spectrometry, even though residual deglycosylation activity was observed in these lines. This argues for low residual protein expression below the detection threshold of MS3, but sufficient, in the cellular environment, to generate enough enzymatic activity in the time-scale of the applied deglycosylation assay.
In conclusion, our systematic approach enabled us to study the prevalence and nature of adverse effects of CRISPR-Cas9-induced frameshift mutations on target protein levels, including alternative splicing and translation reinitiation. Residual protein function of CRISPR-Cas9 frameshift mutations is an important potential limitation of the CRISPR technology for biological research as well as therapeutic applications.
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Methods
Culturing and sequencing of KO clones. HAP1 KO clones were obtained from Horizon Discovery. Cells were grown in IMDM (Gibco, 21980-032) supplemented with 10% FCS (Gibco, 10270) and collected at 70-90% confluency. Gene target indels from KO cell lines were checked by Sanger sequencing (Sequiserve) from cells with similar passage number as those used to derive transcriptomics and proteomics samples.
RNA sequencing. For the quantification of RNA levels, two sequencing techniques were employed. In the technique used for the data shown in Fig. 1a , each KO line was measured by 3′-RNA-seq 23 to a depth of two million reads per sample on average. As this sequencing technique generates reads only at the 3′ end of each transcript molecule, it provides reliable quantification of transcripts at a fraction of the depth that would be needed with shotgun RNA-seq. For the detailed investigation of the subset of 19 KO lines shown in Fig. 1b and the analysis of alternative splicing patterns, KO cell lines were measured with whole-transcript RNA-seq. This technique generates reads throughout all regions of the gene body, and it resulted in a depth of 27 million reads per sample on average. 3′ RNA sequencing. Total RNA was isolated from two to three million HAP1 cells using the Direct-zol-96 RNA kit (Zymo Research) according to the manufacturer's protocol. RNA concentration and integrity were determined on a Fragment Analyzer (Advanced Analytical). cDNA libraries for 3′ mRNA sequencing were prepared from 500 ng of total RNA using the QuantSeq 3′ mRNA-Seq Library Prep Kit FWD for Illumina (Lexogen) according to the manufacturer's protocol. For library amplification, 12 PCR cycles were applied and 45-48 libraries were pooled for sequencing on HiSeq 2000 or HiSeq 2500 instruments (Illumina) using 50-bp single-end reads.
Whole-transcript RNA sequencing. Total RNA was isolated from two to three million HAP1 cells using the Direct-zol-96 RNA kit (Zymo Research) according to the manufacturer's protocol. RNA concentration and integrity were determined on a Fragment Analyzer (Advanced Analytical). Preparation of cDNA libraries was done with the TruSeq RNA Library Prep Kit v2 from Illumina according to the manufacturer's instructions. cDNA was amplified by 15 PCR cycles and 10-11 samples were pooled before sequencing of 100-bp single-end reads on a HiSeq 4000 instrument (Illumina).
Data analysis.
RNA-seq reads were aligned with STAR v.2.5.3a 41 to the Human Reference Genome GRCh37. Mapping of reads to the genome and the presence of frameshift mutations were investigated with IGV 42 . Differential expression analysis was performed using the R/Bioconductor package DESeq2 43 . Sashimi plots were generated using the R/Bioconductor package Gviz 44 and gene models were obtained from ENSEMBL using biomaRt 45 .
MS3 proteomics. Cells were collected by scraping into cold PBS, washed and snap-frozen in liquid nitrogen. Lysis was performed in 2% SDS for 3 min at 95 °C in a thermomixer (Thermo Fisher Scientific), followed by digestion of DNA with benzonase at 37 °C for 1.5 h. Lysate was cleared by centrifugation and the protein concentration in the supernatant was determined by BCA assay. Proteins were reduced by Tris(2-carboxyethyl)phosphine (TCEP) and alkylated with chloroacetamide, separated on 4-12% NuPAGE (Invitrogen) and stained with colloidal Coomassie before proceeding to trypsin digestion. Alternatively, proteins were digested following a modified solid-phase-enhanced sample preparation protocol 46 . In brief, proteins in 2% SDS were bound to Paramagnetic beads (SeraMag Speed beads, GE Healthcare, 45152105050250 and 651521050502) on filter plates (Multiscreen, Merck-Millipore, 10675743) and filled to 50% ethanol. After four washes of the beads with 200 μl of 70% ethanol, beads were resuspended in trypsin and LysC in 0.1 mM HEPES, pH 8.5 containing TCEP and chloroacetamide and incubated at room temperature overnight. Peptides were collected and after lyophilization subjected to TMT labeling.
E. coli spiked into human protein background were produced by a tryptic digest of an E. coli as described above. Peptides were pooled and separated at defined ratios before TMT labeling. The human background consisted of pooled tryptic digests from human cell lysates labeled with TMT.
Peptides were labeled with isobaric mass tags (TMT10; Thermo Fisher Scientific) using the 10-plex TMT reagents, enabling relative quantification of ten conditions in a single experiment 47, 48 . The labeling reaction was performed in 40 mM triethylammonium bicarbonate or 100 mM HEPES, pH 8.5 at 22 °C and quenched with glycine. Labeled peptide extracts were combined to a single sample per experiment and lyophilized.
Sample preparation for mass spectrometry, prefractionation. Lyophilized samples were resuspended in 1.25% ammonia in water. The whole sample was injected onto a precolumn (2.1 mm × 10 mm, C18, 3.5 μm (Xbridge, Waters)) at a flow rate of 15 μl min −1 . Separation was done at 40 μl min −1 on a reversed-phase column (1 mm × 150 mm, C18, 3.5 μm (Xbridge, Waters)) with a 115-min-long gradient ranging from 97% buffer A (1.25% ammonia in water) to 60% B (1.25% ammonia in 70% acetonitrile in water) 49 .
Liquid chromatography with tandem mass spectrometry. Samples were dried in vacuo and resuspended in 0.05% trifluoroacetic acid in water. Half of the sample was injected into an Ultimate3000 nanoRLSC (Dionex) coupled to a Q-Exactive or Orbitrap Fusion Lumos (Thermo Fisher Scientific). Peptides were separated on custom-made 50 cm × 100 μm (ID) reversed-phase columns (Reprosil) at 55 °C. Gradient elution was performed from 2% acetonitrile to 30% acetonitrile in 0.1% formic acid and 3.5% DMSO over 1 or 2 h. Q-Exactive plus mass spectrometers were operated with a data-dependent top ten method. Mass spectra were acquired using a resolution of 70.000 and an ion target of 3 × 10 6 . Higher energy collisional dissociation (HCD) scans were performed with 33% normalized collision energy (NCE) at 35.000 resolution (at an m/z of 200), and the ion target setting was set to 2 × 10 5 to avoid ion coalescence 48 . The instruments were operated with Tune 2.2 or 2.3 and Xcalibur 2.7 or 3.0.63.
Synchronous precursor selection MS3 experiments were performed on an Orbitrap Fusion Lumos operated with fixed cycle time of 2 s. Mass spectra were acquired at a resolution of 60.000 and an ion target of 4 × 10 5 . Tandem mass spectra were acquired in the linear ion trap following HCD fragmentation performed at 38% NCE and an ion target of 1 × 10 4 . MS3 were performed synchronously on the five most abundant MS2 signals in the m/z range of 400-2,000 using HCD at 70% NCE in the Orbitrap at a resolution of 30.000 and an ion target of 1 × 10 5 . The instrument was operated with Tune 2.1.1565.23 and Xcalibur 4.0.27.10. Targeted data acquisition in combination with synchronous precursor selection was performed according to Savitski et al. 50 , employing the settings described above.
Peptide and protein identification. Mascot 2.4 (Matrix Science) was used for protein identification by using a ten parts per million mass tolerance for peptide precursors and 20 mD (HCD) mass tolerance for fragment ions. The search database consisted of a UniProt protein sequence database combined with a decoy version of this database created by using scripts supplied by Matrix Science. Carbamidomethylation of cysteine residues and TMT modification of lysine residues were set as fixed modifications. Methionine oxidation, and N-terminal acetylation of proteins and TMT modification of peptide N-termini were set as variable modifications. We accepted protein identifications as follows. (1) For single spectrum to sequence assignments, we required this assignment to be the best match and a minimum Mascot score of 31 and a 10× difference of this assignment over the next best assignment. On the basis of these criteria, the decoy search results indicated <1% false-discovery rate (FDR). (2) For multiple spectrum to sequence assignments, and using the same parameters, the decoy search results indicated <0.1% FDR. Quantified proteins were required to contain at least two unique peptide matches. FDR for quantified proteins was <0.1%.
Isobaric-mass-tag-based quantification. Reporter ion intensities were read from raw data and multiplied with ion accumulation times (the unit is milliseconds) so as to yield a measure proportional to the number of ions; this measure is referred to as ion area 51 . Spectra matching to peptides were filtered according to the following criteria: mascot ion score > 15, signal-to-background of the precursor ion > 4 and signal-to-interference > 0.5 for MS2-based quantification 51 . Fold changes were corrected for isotope purity as described and adjusted for interference caused by co-elution of nearby isobaric peaks as estimated by the signal-to-interference measure 51 . MS3-based quantification was performed identically but excluding the adjustment for interference caused by co-elution of nearby isobaric peaks. Protein quantification was derived from individual spectra matching to distinct peptides by using a sum-based bootstrap algorithm; 95% confidence intervals were calculated for all protein fold changes that were quantified with more than three spectra 51 for MS2-based quantification. An automatic outlier removal procedure was performed on proteins with at least five quantified peptide-spectrum matches. In brief, each peptide-spectrum match, and the respective quantification values, were sequentially excluded from the fold change calculation; in cases where the confidence interval was then improved by at least 30%, the given quantification values were permanently excluded from further analyses. Data analysis. Raw mass spectra were analyzed by Mascot and IsobarQuant 52 . Downstream analyses were performed with R and Bioconductor 53 . TMT reporter intensities were used to calculate the residual KO expression, that is, the intensity ratio of the KO line over wild-type HAP1, per spectrum. Missing reporter intensities were imputed with zeros. Residual protein levels of exons were calculated by taking the median of all spectra uniquely mapping to every exon of the protein of interest. Exon annotation was obtained from ENSEMBL using biomaRt 45 and translated to the corresponding amino acid numbers. The position of the spectra was determined as the middle of the identified peptide. Protein domain annotation was obtained from ENSEMBL using biomaRt 45 . All plots were generated using ggplot2 (ref. 54 ).
BRD4 immunoprecipitation. BRD4 immunoprecipitation was performed using two antibodies. Rabbit anti-BRD4 amino acids 1312-1362 (Bethyl Laboratories, A301985A) and rabbit anti-BRD4 (Abcam ab128874). One hundred microliters of AminoLink resin (Thermo Fisher Scientific) was functionalized with antibody. HAP1 WT or HAP1 BRD4 KO lysate (100 µl) was added and incubated for 2 h at 4 °C. Beads were subsequently washed and eluted by adding SDS sample buffer.
